Treating to target in psoriatic arthritis

Area of Science:

• Rheumatology
• Inflammatory Diseases
• Clinical Trials

Background:

• Psoriatic arthritis (PsA) is a chronic inflammatory condition leading to joint damage and reduced quality of life.
• Ongoing joint inflammation in PsA is linked to subsequent functional decline and irreversible damage.
• The "treat-to-target" strategy has transformed rheumatoid arthritis management and is gaining traction for PsA.

Purpose of the Study:

• To evaluate the efficacy of a "treat-to-target" approach in managing psoriatic arthritis.
• To assess whether achieving minimal disease activity criteria improves outcomes in PsA patients.
• To explore the potential of a structured treatment strategy for PsA.

Main Methods:

• Review of existing literature on "treat-to-target" in PsA.
• Analysis of preliminary data from the "Tight Control of PsA Study" (a randomized controlled trial).
• Utilizing minimal disease activity criteria as a treatment target.

Main Results:

• Previous reviews found limited evidence for "treat-to-target" in PsA (2011 EULAR review).
• The development of minimal disease activity criteria provides a defined treatment target.
• Preliminary results from the "Tight Control of PsA Study" demonstrate significant improvements in joint and skin activity, and patient-reported outcomes.

Conclusions:

• Early evidence suggests that a "treat-to-target" strategy is beneficial for psoriatic arthritis.
• Further research is necessary to refine and optimize treatment pathways for diverse PsA subtypes.
• The "treat-to-target" approach holds potential for improving long-term outcomes in PsA management.